DNL Stock Overview
Diurnal Group plc operates as a specialty pharma company worldwide.
Diurnal Group Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||UK£0.11|
|52 Week High||UK£0.68|
|52 Week Low||UK£0.10|
|1 Month Change||-14.00%|
|3 Month Change||-35.82%|
|1 Year Change||-83.46%|
|3 Year Change||-65.32%|
|5 Year Change||-91.79%|
|Change since IPO||-92.97%|
Recent News & Updates
|DNL||GB Biotechs||GB Market|
Return vs Industry: DNL underperformed the UK Biotechs industry which returned -40.3% over the past year.
Return vs Market: DNL underperformed the UK Market which returned -8.6% over the past year.
|DNL Average Weekly Movement||4.9%|
|Biotechs Industry Average Movement||6.5%|
|Market Average Movement||5.5%|
|10% most volatile stocks in GB Market||10.8%|
|10% least volatile stocks in GB Market||2.8%|
Stable Share Price: DNL is not significantly more volatile than the rest of UK stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: DNL's weekly volatility (5%) has been stable over the past year.
About the Company
Diurnal Group plc operates as a specialty pharma company worldwide. The company develops hormone therapeutics for the treatment of chronic endocrine conditions, including congenital adrenal hyperplasia, adrenal insufficiency, hypogonadism, and hypothyroidism. The company offers an oral formulation of hydrocortisone granules in capsules for the treatment of pediatric adrenal insufficiency.
Diurnal Group Fundamentals Summary
|DNL fundamental statistics|
Is DNL overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|DNL income statement (TTM)|
|Cost of Revenue||UK£891.00k|
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.079|
|Net Profit Margin||-252.54%|
How did DNL perform over the long term?See historical performance and comparison
Is DNL undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 3/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for DNL?
Other financial metrics that can be useful for relative valuation.
|What is DNL's n/a Ratio?|
Price to Sales Ratio vs Peers
How does DNL's PS Ratio compare to its peers?
|DNL PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
Price-To-Sales vs Peers: DNL is good value based on its Price-To-Sales Ratio (3.5x) compared to the peer average (68x).
Price to Earnings Ratio vs Industry
How does DNL's PE Ratio compare vs other companies in the U.K. Biotechs Industry?
Price-To-Sales vs Industry: DNL is good value based on its Price-To-Sales Ratio (3.5x) compared to the UK Biotechs industry average (19x)
Price to Sales Ratio vs Fair Ratio
What is DNL's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||3.5x|
|Fair PS Ratio||27.5x|
Price-To-Sales vs Fair Ratio: DNL is good value based on its Price-To-Sales Ratio (3.5x) compared to the estimated Fair Price-To-Sales Ratio (27.5x).
Share Price vs Fair Value
What is the Fair Price of DNL when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate DNL's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate DNL's fair value for valuation analysis.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate DNL's PEG Ratio to determine if it is good value.
Discover undervalued companies
How is Diurnal Group forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Future Growth Score2/6
Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: DNL is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: DNL is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: DNL is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: DNL's revenue (63.3% per year) is forecast to grow faster than the UK market (4.1% per year).
High Growth Revenue: DNL's revenue (63.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if DNL's Return on Equity is forecast to be high in 3 years time
Discover growth companies
How has Diurnal Group performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: DNL is currently unprofitable.
Growing Profit Margin: DNL is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: DNL is unprofitable, but has reduced losses over the past 5 years at a rate of 5.6% per year.
Accelerating Growth: Unable to compare DNL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: DNL is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.4%).
Return on Equity
High ROE: DNL has a negative Return on Equity (-44.59%), as it is currently unprofitable.
Discover strong past performing companies
How is Diurnal Group's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: DNL's short term assets (£34.4M) exceed its short term liabilities (£4.6M).
Long Term Liabilities: DNL's short term assets (£34.4M) exceed its long term liabilities (£72.0K).
Debt to Equity History and Analysis
Debt Level: DNL is debt free.
Reducing Debt: DNL has no debt compared to 5 years ago when its debt to equity ratio was 16.4%.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: DNL has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: DNL has sufficient cash runway for 1.4 years if free cash flow continues to reduce at historical rates of 4.8% each year.
Discover healthy companies
What is Diurnal Group current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate DNL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate DNL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if DNL's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if DNL's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as DNL has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Richard Bungay (52 yo)
Mr. Richard Edward Bungay, BSc, ACA, has been the Chief Financial Officer at Diurnal Group plc since January 16, 2017 and serves as its Interim Chief Executive Officer since April 4, 2022. Mr. Bungay serve...
CEO Compensation Analysis
Compensation vs Market: Richard's total compensation ($USD415.42K) is about average for companies of similar size in the UK market ($USD335.04K).
Compensation vs Earnings: Richard's compensation has been consistent with company performance over the past year.
Experienced Board: DNL's board of directors are considered experienced (6 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: DNL insiders have sold more shares than they have bought in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Diurnal Group plc's employee growth, exchange listings and data sources
- Name: Diurnal Group plc
- Ticker: DNL
- Exchange: AIM
- Founded: 2015
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: UK£18.245m
- Shares outstanding: 169.72m
- Website: https://www.diurnal.co.uk
Number of Employees
- Diurnal Group plc
- Cardiff MediCentre
- Heath Park
- South Glamorgan
- CF14 4UJ
- United Kingdom
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/06/26 00:00|
|End of Day Share Price||2022/06/24 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.